The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial launch generated substantial gains, the end of its patent opened the door to off-brand alternatives, https://bookmarkangaroo.com/story21785275/viagra-and-pharma-a-precarious-opportunity